Abstract: A nanosecond pulser system is disclosed. In some embodiments, the nanosecond pulser system may include a nanosecond pulser having a nanosecond pulser input; a plurality of switches coupled with the nanosecond pulser input; one or more transformers coupled with the plurality of switches; and an output coupled with the one or more transformers and providing a high voltage waveform with a amplitude greater than 2 kV and a frequency greater than 1 kHz based on the nanosecond pulser input. The nanosecond pulser system may also include a control module coupled with the nanosecond pulser input; and an control system coupled with the nanosecond pulser at a point between the transformer and the output, the control system providing waveform data regarding an high voltage waveform produced at the point between the transformer and the output.

Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.

Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.

Abstract: Some embodiments of the invention may include an eddy current nondestructive evaluation device. The eddy current nondestructive evaluation device may include a rotating body; a motor coupled with the rotating body such that the motor rotates the rotating body; a permanent magnet coupled with the rotating body; a pickup coil coupled with the rotating body; and an integrator circuit electrically coupled with the pickup coil that integrates a voltage from the pickup coil to produce integrated voltage data.

Abstract: A method for inversion of a path mileage and offset by using a known coordinate point, comprising: based on coordinates of a known point P and curve elements of a start location and an end location of a curve element, first segmenting or not segmenting the curve element according to a corner of the curve element to obtain a plurality of curve sub-elements (AiBi), and calculating curve elements of the curve sub-elements (AiBi); taking any curve sub-element (AiBi) to calculate a half chord length S and a straight corner ?, and performing precision determination and convergence correction according to S and ?, the point P being always effective with respect to the curve sub-element (AiBi) in the correction process; and performing cyclic convergence calculation to finally obtain a distance from the point P to any point on a chord line or an arc line as an offset of the curve sub-element (AiBi) corresponding to the point P and to obtain a mileage of the curve sub-element (AiBi) corresponding to the point P.

Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.

Abstract: A nanosecond pulser system is disclosed. In some embodiments, the nanosecond pulser system may include a nanosecond pulser having a nanosecond pulser input; a plurality of switches coupled with the nanosecond pulser input; one or more transformers coupled with the plurality of switches; and an output coupled with the one or more transformers and providing a high voltage waveform with a amplitude greater than 2 kV and a frequency greater than 1 kHz based on the nanosecond pulser input. The nanosecond pulser system may also include a control module coupled with the nanosecond pulser input; and an control system coupled with the nanosecond pulser at a point between the transformer and the output, the control system providing waveform data regarding an high voltage waveform produced at the point between the transformer and the output.

Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.

Abstract: A method for inversion of a path mileage and offset by using a known coordinate point, comprising: based on coordinates of a known point P and curve elements of a start location and an end location of a curve element, first segmenting or not segmenting the curve element according to a corner of the curve element to obtain a plurality of curve sub-elements (AiBi), and calculating curve elements of the curve sub-elements (AiBi); taking any curve sub-element (AiBi) to calculate a half chord length S and a straight corner ?, and performing precision determination and convergence correction according to S and ?, the point P being always effective with respect to the curve sub-element (AiBi) in the correction process; and performing cyclic convergence calculation to finally obtain a distance from the point P to any point on a chord line or an arc line as an offset of the curve sub-element (AiBi) corresponding to the point P and to obtain a mileage of the curve sub-element (AiBi) corresponding to the point P.

Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.

Abstract: The invention is a copper alloy with excellent comprehensive performance, including the following components in percentage by weight: 0.4 wt %-2.0 wt % of Ni, 0.2 wt %-2.5 wt % of Sn, 0.02 wt %-0.25 wt % of P, 0.001 wt %-0.5 wt % of Si, and the balance of Cu and unavoidable impurities. The copper alloy has a yield strength of 550 MPa or above, and an electrical conductivity of 38% IACS or above. A bending workability is as follows: the value of R/t in the GW direction is less than or equal to 1, and the value of R/t in the BW direction is less than or equal to 2; and after the copper alloy is kept at 150° C. for 1000 hours, a residual stress rate is greater than or equal to 75%, and the stress relaxation resistance is excellent.

Abstract: The present invention provides piperidin-4-y1 azetidine derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase 1 (JAK1) and are useful in the treatment of diseases related to the activity of JAK1 including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.

Abstract: The invention is a precipitation-strengthened copper alloy, including the following components in percentage by weight: 80 wt %-95 wt % of Cu, 0.05 wt %-4.0 wt % of Sn, 0.01 wt %-3.0 wt % of Ni, 0.01 wt %-1.0 wt % of Si, and the balance of Zn and unavoidable impurities. According to the invention, the comprehensive performance of the alloy is improved by solution strengthening and precipitation strengthening; while the strength of the matrix is improved, the electrical conductivity of the alloy is hardly affected, the bending workability meets the requirements, and the stress relaxation resistance comparable to that of tin phosphor bronze is achieved. The comprehensive performance of the alloy of the invention is superior to that of the tin phosphor bronze C51900. Furthermore, the alloy of the invention is low in raw material cost, has obvious advantages in welding and plating.

Abstract: A method and apparatus is described to push to-be-recommended products onto users' terminals based on similarities in the to-be-recommended products and products in the users' historical records of products. To improve the pushed recommendations various technics are applied, including: using predefined criteria to filter products provided from the users' historical records, applying temporal decay to provide real-time recommendations, removing already obtained products from the to-be-recommended products to be pushed, improving similarity calculations by determining similarity using pairwise variations between products both in and out of the candidates for to-be-recommended products, sorting the to-be-recommended product according to a preset recommendation policy, calculating pairwise variations using multiple types of similarity measures, using weights to determine the to-be-recommended products, and applying a preset recommendation policy based on a given scenario.

Abstract: An air conditioner includes a housing. The housing includes a panel including an opening. The air conditioner further includes an indicator light arranged at the opening, an air heat exchange duct and an air treatment duct arranged in the housing and not in communication with each other, an air heat exchange device arranged at the air heat exchange duct and configured to conduct heat exchange for air in the air heat exchange duct, and an air treatment device arranged at the air treatment duct and configured to conduct at least one of humidification or purification for air in the air treatment duct.

Abstract: Disclosed are combination therapies comprising administration of a CD73 inhibitor, an adenosine A2A or A2B receptor inhibitor, and a PD-1/PD-L1 inhibitor. The disclosed combination therapies are useful in the treatment of diseases related to the activity of adenosine receptors and/or CD73 and/or PD-1/PD-L1 including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases. Anti-CD73 antibodies, PD-1/PD-L1 inhibitors, and A2A/A2B inhibitors are also disclosed.

Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.

Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.

Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.